GLASSIA + methylprednisolone or equivalent steroid + Albumin
Phase 2/3Terminated 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graft Versus Host Disease
Conditions
Graft Versus Host Disease
Trial Timeline
Apr 26, 2017 → May 3, 2018
NCT ID
NCT02956122About GLASSIA + methylprednisolone or equivalent steroid + Albumin
GLASSIA + methylprednisolone or equivalent steroid + Albumin is a phase 2/3 stage product being developed by Kamada for Graft Versus Host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT02956122. Target conditions include Graft Versus Host Disease.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02956122 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Graft Versus Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prograf + Methotrexate + Cyclosporine | Astellas Pharma | Approved | 85 |
| Alefacept | Astellas Pharma | Phase 2 | 52 |
| tacrolimus | Astellas Pharma | Approved | 85 |
| Tacrolimus + Tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Itolizumab + EQ001 Placebo | Biocon | Phase 3 | 77 |
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 41 |
| SHR0302 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Acalabrutinib | AstraZeneca | Phase 2 | 52 |
| Aspirin + Ticagrelor | AstraZeneca | Approved | 85 |
| Sugammadex | Merck | Approved | 85 |
| Efprezimod alfa + Methotrexate + Tacrolimus + Placebo | Merck | Phase 2 | 52 |
| Ruxolitinib | Novartis | Approved | 85 |
| Imatinib Mesylate and Nilotinib | Novartis | Phase 2 | 52 |
| Prednisone + Jakavi(ruxolitinib) + Prednisone | Novartis | Phase 2 | 52 |
| PredEver | Novartis | Phase 2 | 52 |
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 33 |
| Cyclosporine | Novartis | Approved | 85 |
| Everolimus + Tacrolimus + Mycophenolic acid | Novartis | Approved | 85 |
| 1 + 2 | Novartis | Approved | 85 |